References
1 Savige J, Storey H, Watson E, et al. Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria[J]. Eur J Hum Genet, 2021, 29(8): 1186-1197. PMID: 33854215. PMCID: PMC8384871. DOI: 10.1038/s41431-021-00858-1.
2 Matthaiou A, Poulli T, Deltas C. Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review[J]. Clin Kidney J, 2020, 13(6): 1025-1036. PMID: 33391746. PMCID: PMC7769542. DOI: 10.1093/ckj/sfz176.
3 赵颖玲, 于力. Alport综合征的临床表现及诊疗进展[J]. 罕少疾病杂志, 2022, 29(4): 1-4. DOI: 10.3969/j.issn.1009-3257.2022.04.001.
4 Kashtan CE. Alport syndrome: achieving early diagnosis and treatment[J]. Am J Kidney Dis, 2021, 77(2): 272-279. PMID: 32712016. DOI: 10.1053/j.ajkd.2020.03.026.
5 Alport综合征诊疗共识专家组. Alport综合征诊断和治疗专家推荐意见[J]. 中华肾脏病杂志, 2018, 34(3): 227-231. DOI: 10.3760/cma.j.issn.1001-7097.2018.03.014.
6 Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424. PMID: 25741868. PMCID: PMC4544753. DOI: 10.1038/gim.2015.30.
7 王卫平, 孙锟, 常立文, 等. 儿科学[M]. 9版. 北京: 人民卫生出版社, 2018: 296.
8 安晓刚, 张琰琴, 丁洁, 等. Alport综合征单中心临床诊治状况分析[J]. 中华儿科杂志, 2016, 54(9): 669-673. PMID: 27596081. DOI: 10.3760/cma.j.issn.0578-1310.2016.09.008.
9 于小勇. 2022年美国医学遗传学与基因组学学会/分子病理学协会Alport综合征管理和基因检测指南[J]. 陕西医学杂志, 2023, 52(3): 243-251. DOI: 10.3969/j.issn.1000-7377.2022.03.001.
10 Mencarelli MA, Heidet L, Storey H, et al. Evidence of digenic inheritance in Alport syndrome[J]. J Med Genet, 2015, 52(3): 163-174. PMID: 25575550. DOI: 10.1136/jmedgenet-2014-102822.
11 Choi M, Anistan YM, Eckardt KU, et al. Possible digenic disease in a Caucasian family with COL4A3 and COL4A5 mutations[J]. Nephron, 2019, 141(3): 213-218. PMID: 30661074. DOI: 10.1159/000495764.
12 Zhang Y, Ding J, Zhang H, et al. Effect of heterozygous pathogenic COL4A3 or COL4A4 variants on patients with X-linked Alport syndrome[J]. Mol Genet Genomic Med, 2019, 7(5): e647. PMID: 30883042. PMCID: PMC6503168. DOI: 10.1002/mgg3.647.
13 胡宁宁, 戴选彤, 蒋更如, 等. 双基因突变型X连锁Alport综合征女性患者临床与遗传学特征分析[J]. 上海医学, 2021, 44(6): 434-442. DOI: 10.19842/j.cnki.issn.0253-9934.2021.06.016.
14 Savige J, Lipska-Zietkiewicz BS, Watson E, et al. Guidelines for genetic testing and management of Alport syndrome[J]. Clin J Am Soc Nephrol, 2022, 17(1): 143-154. PMID: 34930753. PMCID: PMC8763160. DOI: 10.2215/CJN.04230321.
15 Zhang X, Zhang Y, Zhang Y, et al. X-linked Alport syndrome: pathogenic variant features and further auditory genotype-phenotype correlations in males[J]. Orphanet J Rare Dis, 2018, 13(1): 229. PMID: 30577881. PMCID: PMC6303895. DOI: 10.1186/s13023-018-0974-4.
16 成艳辉. Alport综合征患儿临床表型与基因型分析[D]. 西安: 西安医学院, 2022.
17 Zhao X, Chen C, Wei Y, et al. Novel mutations of COL4A3, COL4A4, and COL4A5 genes in Chinese patients with Alport syndrome using next generation sequence technique[J]. Mol Genet Genomic Med, 2019, 7(6): e653. PMID: 30968591. PMCID: PMC6565573. DOI: 10.1002/mgg3.653.
18 Plant KE, Boye E, Green PM, et al. Somatic mosaicism associated with a mild Alport syndrome phenotype[J]. J Med Genet, 2000, 37(3): 238-239. PMID: 10777371. PMCID: PMC1734534. DOI: 10.1136/jmg.37.3.238.
19 Navarro-Cobos MJ, Balaton BP, Brown CJ. Genes that escape from X-chromosome inactivation: potential contributors to Klinefelter syndrome[J]. Am J Med Genet C Semin Med Genet, 2020, 184(2): 226-238. PMID: 32441398. PMCID: PMC7384012. DOI: 10.1002/ajmg.c.31800.
20 Queremel Milani DA, Chauhan PR. Genetics, Mosaicism[M]//StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.